Hemofarm A.D. DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Virtual Booth

Contact Supplier

Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

1 News #PharmaBuzz

media
1 News #PharmaBuzz

INSPECTIONS & REGISTRATIONS

11 EDQM

inspections
11 EDQM

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Hemofarm’s core activity is production of high-quality, safe, effective and available generic pharmaceutical products by applying high-end technologies. Hemofarm manufactures medicinal products of all pharmaco-therapeutic groups and forms, from simplest to most complex ones: it sells products of 12 (out of 14) pharmaco-therapeutic groups according to the ATC classification, portfolio contains 192 products by INN, with 388 forms and dosages, portfolio is focused on most important pharmaco-therapeutic groups, such as products for cardiovascular diseases, antibiotics and neuropsychiatric products, over-the-counter (OTC) products have a leading position in the Serbian pharmaceutical market, with a share exceeding 13%, constant improvement of portfolio with new generations of medicines, development of new segments, primarily oncology. Hemofarm is a leader in the local market of pharmaceuticals, competing against 300 manufacturers and distributors1, with a share of 34% in goods, i.e. 17.5% in value. Business operations within STADA Group open additional possibilities for sales of products to very demanding EU markets. The new strategic portfolio approach has been ‘tailor-made’ to suit the requirements of each region.it sells products of 12 (out of 14) pharmaco-therapeutic groups according to the ATC classification, portfolio contains 192 products by INN, with 388 forms and dosages, portfolio is focused on most important pharmaco-therapeutic groups, such as products for cardiovascular diseases, antibiotics and neuropsychiatric products, over-the-counter (OTC) products have a leading position in the Serbian pharmaceutical market, with a share exceeding 13%, constant improvement of portfolio with new generations of medicines, development of new segments, primarily oncology. Hemofarm is a leader in the local market of pharmaceuticals, competing against 300 manufacturers and distributors1, with a share of 34% in goods, i.e. 17.5% in value. Business operations within STADA Group open additional possibilities for sales of products to very demanding EU markets. The new strategic portfolio approach has been ‘tailor-made’ to suit the requirements of each region.